Perficient Acquires BioPharm Systems
BioPharm Systems, a global IT consulting and managed services provider in the life sciences industry, has been acquired by Perficient.
BioPharm Systems, a global IT consulting and managed services provider in the life sciences industry, has been acquired by Perficient, a global IT consulting firm in many vertical markets. The acquisition of BioPharm Systems is Perficient's first in the life sciences space. According to a press release, the acquisition gives Perficient its vertical expertise in life sciences, specially in clinical trial management, clinical data management and safety and pharmacovigilance solutions; strengthens the company's Oracle-based partnerships and capabilities and adds life sciences clients including Bayer, CR Bard, Halozyme Therapeutics, Ikaria, Johnson & Johnson, Medtronic, Pfizer, St. Jude Medical, Stryker, and Sunovion. BioPharm Systems President and CEO Alex Sefanov joins the company in a key leadership role, as do 50 other professionals from the company.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
